Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I sold, I'm chicken!
Good Morning all!
Trifecta, $ONCI $SNMN $FUTL!
$ONCI $SNMN $FUTL
Here is another one to look at, $FUTL
Good morning all, Looks like we are just playing OTC's for now!
Thank you buddy,Go $SNMN
Morning Dip & Rippers!
Awesome, Thanks i'll take a closer look!
Something might be up, $HTBX 0.535 0.00 0.00 16,289 0.57 0.59
? $EYES 1.27 0.00 0.00 33,275 1.30 1.33
I sold half today @ .01 rest are free!
Thanks Pharaoh, $ONCI still doing very well!
Close watch for entry, $LINU 1.37 0.00 0.00 63,446 1.50 1.55
LiNiu Technology Group Announces Strategic Cooperation Agreement with The Peoples Insurance Company of China Limited's Guangzhou Branch
55 minutes ago - DJNF
HONG KONG--(BUSINESS WIRE)--September 11, 2017--
LiNiu Technology Group (f/k/a Iao Kun Group Holding Company Limited) ("LINU" or the "Company") (NASDAQ: LINU), which launched its electronic trading platform focused on the Chinese agricultural industry in April 2017 through Guangzhou LiNiu Network Technology Co., Ltd. ("Guangzhou LiNiu"), today announced that it has signed a three-year strategic cooperation agreement with The Peoples Insurance Company of China Limited's ("PICC") Guangzhou branch.
PICC, a listed company on the Hong Kong Stock Exchange, which engages in property and casualty insurance, life and health insurance, asset management and financial services, is one of the largest insurance financial groups in China. Total gross written premiums for PICC in 2016 were approximately RMB439.8 billion. Within that total, gross written premiums from agriculture insurance were approximately RMB19.5 billion, and PICC also generated gross written premiums of approximately RMB36 billion from contracts written in Guangdong province.
Through the agreement, the companies will work together to develop new insurance products tailored for farmers, rural residents and the agricultural industry that would help in solving the Three Rural Issues. Guangzhou LiNiu will also prioritize the promotion of PICC's insurance products to customers of its LiNiuYang trading platform, while PICC in turn will promote LiNiuYang's products, services and platform to its customers through brochures or booths in its branch offices. In addition, both companies will meet regularly and share knowledge and information to help improve their efficiency through enhanced risk management, information management and e-commerce development.
"We are pleased to be working closely with PICC to help further enhance our presence in Guangdong province while devising new products in concert with PICC that should provide additional benefits to customers of our LiNiuYang platform," said Mr. Wang Shun Yang, co-Chief Executive Officer of LiNiu Technology Group.
About LiNiu Technology Group
LiNiu Technology Group (NASDAQ: LINU) recently launched the LiNiu Network, a Business to Customer ("B2C"), Customer to Customer ("C2C") and Online to Offline ("O2O") electronic trading platform focused on the Chinese agricultural industry. The Company also currently participates in the promotion of VIP gaming at the Altira Macau. For more information on the LiNiu Network, please visit www.liniuyang.com.
Forward-Looking Statements
This press release includes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements, based upon the current beliefs and expectations of the Company's management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Factors that could cause actual results to differ materially from management's current expectations include but not limited to those risks and uncertainties relating to future business development; ability to maintain the reputation and brand; privacy and regulatory concerns; competition; security breaches; the continued growth of the e-commerce market in China; and fluctuations in general economic and business conditions in China and assumptions underlying or related to any of the foregoing. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law. Investors and potential investors should consult all of the information set forth herein and should also refer to the risk factors set forth in the Company's Annual Report on Form 20-F filed in April 2017, and other reports filed or to be filed from time-to-time with the Securities and Exchange Commission.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170911005590/en/
CONTACT: LiNiu Technology Group
Ryan Yip, +852 2111 9220
ryany@liniuyang.com
SOURCE: LiNiu Technology Group
Copyright Business Wire 2017
(END) Dow Jones Newswires
September 11, 2017 08:30 ET (12:30 GMT)
Good morning all, Praying all are friends and family are safe!
He is down in the hurricane;s path, Prayers out to him and his family.
Also everyone else effected by the hurricane!
$ONCI repost,
DJknows Friday, 09/08/17 04:52:46 PM
Re: None
Post # of 95201
Wonder how this list will change and/or expand (even as early as tonight):
On4 COMMUNICATIONS BUSINESS TRANSACTIONS SINCE DECEMBER 2016
CEO plans to retire 1.4B shares
October 2017 - Heading to ASIA for expansion… various potential deals involving cell phone companies and fleet business
October 19, 2017 - Meeting with GENERAL MOTORS CORP. in DETROIT, MI
September or Oct. or - follow-up meetings with Mayor of SAN ANTONIO, TX and Governor of MICHIGAN
By September 30, 2017 - Engineering changes completed to FMS app to present to CHRYSLER at its request following August 31st meeting… could begin pilot rollout
September 27, 2017 - Meeting with FORD MOTOR COMPANY for potential national/global rollout of FMS App
September 15, 2017 - Expecting Q3 to be filed
September 15, 2017 - Meeting at BMW in GERMANY regarding FMS App
By September 15, 2017 - NEW WEBSITE
September 8, 2017 - All NDAs (Non-Disclosure Agreement) expire allowing announcement of the name of the acquired partner and apps being sold and beta tested
September 7, 2017 - CEO Steve Berman goes to EUROPE for meetings with various auto industry potential deals and testing with designers of five new apps: two in Auto Safety, two in Sports Gaming and one MJ related
September 6, 2017 - Meeting with ENTERPRISE RENT-A-CAR about FMS app and Tracking Device
September 1, 2017 - ONCI announces receiving stamp for HEXAGON HOLDINGS CORPORATION from CO-SOS and their SEC Attorney will be filing with FINRA for name change … HEXAGON will have 6 divisions
September 1, 2017 - Announced signing contract with 10 DEALER GROUP IN ARIZONA
September 1, 2017 - ONCI announces acquiring remaining 51% of FMS for $3.5M through non-dilutive funding for 100% control... acquisition also includes a fleet business
August 31, 2017 - Meeting with CHRYSLER CORP. IN MICHIGAN
August 29, 2017 - Announced seeking to acquire additional 7500sf manufacturing facility in Kuala Lumpur... would have total 22,500sf
August 29, 2017 - Executed a contract with a 5 DEALER AUTO GROUP IN LONG ISLAND, NY with brands including Toyota, Nissan Chevy, Kia and Ford… receiving units by 9/18/17
August 24, 2017 - Following 8/22 meeting in California, FORD FLEET SERVICES asked ONCI to put 1000 units on reserve as they have a Large Mid-Western Utility Company that has expressed interest in not only the FMS Safe Driving App but also the Global Tracking Device
August 22, 2017 - Meeting with FLETCHER JONES AUTO in California
August 21, 2017 - Executed a contract with a large MID-ATLANTIC DEALER GROUP with locations in Virginia, Maryland, Delaware and Washington DC
August 17, 2017 - Signed a deal with a large luxury dealer group in TEXAS including such brands as Mercedes, BMW, Lexus, Audi, Lincoln, Cadillac, Porsche and Infiniti… units to be delivered by 9/13/17
August 11 2017 - Executed a contract with GOOGLE BRAZIL for online sales… could be similar deals with Google Argentina, Peru, Chile, Columbia, Paraguay and Venezuela
August 3, 2017 - Partnered deal with ASSURANT ARGENTINA
August 1, 2017 - Entered into a marketing agreement with one of the largest worldwide online shopping sites with access to over 50 million customers…FMS App… sales start 8/12
July 27, 2017 - ONCI announces agreement with a large SOUTH FLORIDA LAW FIRM representing over 500 auto dealers
June 26, 2017 - Signed a deal with a leading Auto Dealer Group in South America representing Nissan, Toyota, GM, Ford, Land Rover, Kia and Hyundai
June 15, 2017 - Posted Q2 record quarterly revenues of $307,750.00 = +486% Q/Q … following week ONCI became ‘CURRENT’ on OTC Markets
April 19, 2017 - Received a $100K order for Drive Safe App from one of the leading Asian auto manufacturers with HQ’s based in KOREA and JAPAN… Japanese Insurance company
January 24, 2017 - Secured eight new Auto Dealer Vendors in Florida for FMS Drive Safe App.
December 23, 2016 - Drive Safe App installed on a large Taxi fleet in the North-East USA, first 250 vehicles during the 2nd week of January 2017 increasing until full installation has been completed in the company’s 1500 vehicle Taxi fleet
December 19, 2016 - Launch of proprietary Drive Safe App with a large Food & Beverage distributor
So ONCI already has signed deals with the following:
ASSURANT ARGENTINA: $1,200,000 annual revs (8/3/17)
GOOGLE BRAZIL: $600,000 annual revs with plans for expansion in several more South American countries (8/11/17)
FLORIDA LAW GROUP: $600,000 annual revs
SHOPPING WEBSITE: $600,000 annual revs est (8/1/17)
BRAZIL EXTENDED WARRANY Company: $2,000,000 annual revs est
SOUTH AMERICAN Group: $1,800,000 annual revs est (6/26/17)
FLORIDA 8 Vendor dealers: $670,000 annual revs (1/24/17)
TEXAS Luxury Auto Group: $480,000 annual revs (8/17/17)
MID ATLANTIC 12 dealers $432,000 annual revs (8/21/17)
Five Dealers Long Island NY: $360,000 annual revs (8/29/17)
Ten Dealer group in ARIZONA: $450,000 annual revs (9/1/17)
Hey everyone have a great weekend.
As for anyone in florida, Your in my prayers. Be safe!
What short squeeze? 52 week high was only .0048. All shorts had to cover, Correct?
Go $ONCI
On news, $OPGN 0.30 0.00 0.00 88,760 0.31 0.33
OpGen Data on New Rapid Gene Test and Antibiotic Susceptibility Prediction Algorithms Presented at the 2017 ASM/ESCMID Conference
39 minutes ago - DJNF
OpGen Data on New Rapid Gene Test and Antibiotic Susceptibility Prediction Algorithms Presented at the 2017 ASM/ESCMID Conference
GAITHERSBURG, Md., Sept. 08, 2017 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today announced that the Company presented study results on the company's new rapid test in development, the Acuitas(R) AMR Gene Panel u5.47, and the Acuitas Lighthouse(R) Knowledgebase for prediction of antibiotic susceptibility at the 2017 ASM/ESCMID Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance. The poster presentation, titled "Predicting Antibiotic Resistance in Gram-Negative Bacilli by Rapid Detection of Resistance Genes," was presented by Terry Walker, Ph.D., OpGen's senior vice president of research and development and the lead author on the study, on September 7, 2017. The conference is being held September 6--8, 2017 at the Boston Park Plaza Hotel.
The poster includes data based on OpGen's analysis of the Merck Study for Monitoring Antimicrobial Resistance Trends (SMART) clinical isolate archive by phenotypic antibiotic susceptibility testing and a high-throughput PCR assay for 126 antibiotic resistance genes. Based on this analysis and additional discovery work, OpGen is developing the Acuitas AMR Gene Panel u5.47, a Research Use Only semi-quantitative PCR test that rapidly detects antibiotic resistance genes. The semi-quantitative PCR test detects 5 bacterial pathogens in clinical isolates and urine specimens and detects 47 antimicrobial resistance genes. The poster highlights in silico prediction results using the Acuitas Lighthouse Knowledgebase to interpret test results from the Acuitas AMR Gene Panel. Results of the study showed that the Acuitas Lighthouse Knowledgebase predicted phenotypic antibiotic resistance for 17 antibiotics based on 47 resistance genes, with agreement ranging from 79% to 97% for E. coli, 78% to 90% for K. pneumoniae; 46% to 84% for P. aeruginosa; and 76% to 99% for P. mirabilis.
"Antimicrobial drug resistance is an urgent global health concern, and there is a pressing need to provide resistance information to healthcare providers more quickly," said Dr. Walker. "Our data show that the Acuitas AMR Gene Panel accurately detects and quantitates key complicated urinary tract infection pathogens. We are encouraged by the development data for Acuitas Lighthouse Knowledgebase prediction algorithms currently in development. The results from this study suggest the AMR Gene Panel can potentially aid in the rapid detection of resistance genes days ahead of antibiotic susceptibility testing, which is the current standard guide for antibiotic therapy. An early identification of antibiotic resistance genes may improve antimicrobial stewardship and patient outcomes."
About ASM/ESCMID
Antimicrobial drug resistance (AMR) is an urgent global health problem. New antimicrobial drug development is increasingly viewed as a priority by National and International bodies. There are relatively few agents in developmental pipelines and a paucity of identified microbiological targets that can be exploited for drug development. Co-sponsored by the American Society for Microbiology (ASM) and the European Society for Clinical Microbiology and Infectious Diseases (ESCMID), this multidisciplinary meeting will address the challenges, opportunities and current requirements for antimicrobial drug development for AMR.
About OpGen
OpGen, Inc. is harnessing the power of informatics and genomic analysis to provide complete solutions for patient, hospital and network-wide infection prevention and treatment.
OpGen, Acuitas, Acuitas Lighthouse and QuickFISH are registered trademarks of OpGen, Inc.
Forward-Looking Statements
This press release includes statements relating to the company's products and services development efforts. These statements and other statements regarding OpGen's future plans and goals constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control, and which may cause results to differ materially from expectations. Factors that could cause our results to differ materially from those described include, but are not limited to, our ability to successfully, timely and cost-effectively develop, seek and obtain regulatory clearance for and commercialize our product and services offerings, the rate of adoption of our products and services by hospitals and other healthcare providers, the success of our commercialization efforts, the effect on our business of existing and new regulatory requirements, and other economic and competitive factors. For a discussion of the most significant risks and uncertainties associated with OpGen's business, please review our filings with the Securities and Exchange Commission (SEC). You are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this press release and speak only as of the date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
OpGen Contact:
Michael Farmer
Sr. Director, Marketing
240-813-1284
mfarmer@opgen.com
InvestorRelations@opgen.com
Investor Contact:
LHA Investor Relations
Kim Sutton Golodetz
212-838-3777
kgolodetz@lhai.com
or
Bruce Voss
310-691-7100
bvoss@lhai.com
(END) Dow Jones Newswires
September 08, 2017 07:30 ET (11:30 GMT)
I only bought a half a milly @ .0033, But thank you so very much!
We all are blessed, Thanks buddy. $ONCI 0.0084
$VVUS 0.8713 0.00 0.00 20,600 0.92 0.93
VIVUS Announces Tacrolimus Receives Orphan Drug Designation in the European Union for the Treatment of Pulmonary Arterial Hypertension
16 hours 41 minutes ago - DJNF
VIVUS Announces Tacrolimus Receives Orphan Drug Designation in the European Union for the Treatment of Pulmonary Arterial Hypertension
CAMPBELL, CA--(Marketwired - September 06, 2017) - VIVUS, Inc. (NASDAQ: VVUS) (the "Company"), a biopharmaceutical company committed to the development and commercialization of innovative therapies focusing on treatments for patients with serious unmet medical needs, today announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation to the Company's lead clinical candidate tacrolimus, for the treatment of pulmonary arterial hypertension (PAH).
"Receiving Orphan Drug Designation from the EMA is an important milestone in our long-term development and commercialization strategy for tacrolimus," said Seth H. Z. Fisher, VIVUS' Chief Executive Officer. "There is an urgent need for new therapies that have the potential to address the underlying cause of PAH, and we are committed to advancing tacrolimus as a novel approach to treating this debilitating disease."
Orphan Drug Designation is awarded for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition that is rare (affecting not more than five in 10,000 people in the European Union) or where the medicine is unlikely to generate sufficient profit to justify research and development costs. This designation provides VIVUS with a number of potential incentives in the EU. Tacrolimus was granted Orphan Drug Designation by the U.S. Food & Drug Administration (FDA) for the treatment of PAH in March 2015.
VIVUS remains on track to hold a pre-IND meeting with the FDA by the end of 2017.
About Pulmonary Arterial Hypertension (PAH)
PAH is a chronic life-threatening disease characterized by elevated blood pressure in the pulmonary arteries (arteries between the heart and lungs) due to severe constriction of these blood vessels. These high pressures make it difficult for the heart to pump blood through the lungs to be oxygenated. The symptoms of PAH are non-specific and can range from mild shortness of breath and fatigue during normal daily activity to symptoms of right heart failure and severe restrictions on exercise capacity and ultimately reduced life expectancy. PAH includes patients with idiopathic PAH, familial PAH, and associated PAH, which is related to certain conditions including connective tissue diseases, congenital systemic-to-pulmonary-shunts, portal hypertension, HIV infection, drugs and toxins. The current treatments for PAH involve calcium channel antagonists, prostacyclins, prostacyclin receptor (IP receptor) agonist, endothelin receptor antagonists, phosphodiesterase-5 (PDE5) inhibitors, and long-term anticoagulant therapy, with the aim to reduce symptoms and improve quality of life.
About VIVUS
VIVUS is a biopharmaceutical company committed to the development and commercialization of innovative therapies that focus on advancing treatments for patients with serious unmet medical needs. For more information about the company, please visit www.vivus.com.
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 and are subject to risks, uncertainties and other factors, including risks and uncertainties related to potential change in our business strategy to enhance long-term stockholder value; risks and uncertainties related to our ability to successfully develop or acquire a proprietary formulation of tacrolimus as a precursor to the clinical development process; risks and uncertainties related to our ability to continue to identify, acquire and develop innovative investigational drug candidates and drugs; risks and uncertainties related to the failure to obtain FDA or foreign authority clearances or approvals and noncompliance with FDA or foreign authority regulations; risks and uncertainties related to our ability to develop a proprietary formulation and to demonstrate through clinical testing the quality, safety, and efficacy of our current or future investigational drug candidates; and risks and uncertainties related to the timing of initiation and completion of clinical trials and submissions to U.S. and foreign authorities. These risks and uncertainties could cause actual results to differ materially from those referred to in these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. Investors should read the risk factors set forth in VIVUS' Form 10-K for the year ended December 31, 2016 as filed on March 8, 2017 and as amended by the Form 10-K/A filed on April 26, 2017, and periodic reports filed with the Securities and Exchange Commission. VIVUS does not undertake an obligation to update or revise any forward-looking statements.
CONTACT:
VIVUS, Inc.
Mark Oki
Chief Financial Officer
oki@vivus.com
650-934-5200
Investor Relations:
Lazar Partners
Matthew Ventimiglia
mventimiglia@lazarpartners.com
212-599-1265
(MORE TO FOLLOW) Dow Jones Newswires
September 06, 2017 16:05 ET (20:05 GMT)
$MGTI 3.16 0.26 +8.97 677,110 3.14 3.16
Alert this morning, $LTBR 1.4202 0.3002 +26.80 813,499 1.41 1.43
Price Open 1.25
Previous Close 1.12
Day High 1.48
Day Low 1.21
On watch, $ARGS 0.2269 0.0229 +11.23 1,109,394 0.2241 0.2269
On news,$LTBR 1.12 0.00 0.00 10,836 1.23 1.25
Good morning guys, I'm loving the new board.
This is my busiest time of the year, in my business.
I'll add what i can on here!
Email me, my alias,@yahoo.com
Thank you,Thank you, Thank you, $ONCI up over 100% since purchase!
$BLPH 1.13 0.00 0.00 130,891 1.27 1.29
Bellerophon Shares Surge 20% Premarket On Positive Results In Trial Of COPD Treatment -- MarketWatch
44 minutes ago - DJNF
Bellerophon Therapeutics Inc. shares (BLPH) surged 20% in premarket trade, after the company reported positive results in a mid-stage trial of a treatment for pulmonary hypertension associated with chronic obstructive pulmonary disease. The company said the phase 2 trial of its INOpulse inhaled nitric oxide met its primary and secondary goals, showing statistically significant improvement in six-minute walking distance, hemodynamics and blood vessel volume. "COPD patients with associated pulmonary hypertension have a poor prognosis with an approximately 4-year life expectancy and high hospitalization rates, which represents a significant unmet medical need for a safe and effective long-term treatment," said Dr. Raymond L. Benza of the Cardiovascular Institute at Allegheny General Hospital, Pittsburgh, PA and Chairman of Bellerophon's PH-COPD steering committee. The company is planning to conduct a larger phase 2b study of the treatment. Shares have gained 117% in 2017, while the S&P 500 has gained 10.6%.
-Ciara Linnane
For more from MarketWatch: http://www.marketwatch.com/newsviewer
(END) Dow Jones Newswires
September 05, 2017 08:40 ET (12:40 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
$NVCN 1.14 0.00 0.00 34,656 1.17 1.18
Neovasc's Reducer System Reviewed in European Heart Journal
2 hours 22 minutes ago - DJNF
Review serves to update clinicians as to current evidence and future perspectives on the optimal utilization of this innovative technology
NASDAQ, TSX: NVCN
VANCOUVER, Sept. 5, 2017 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) today announced the European Heart Journal published a clinical review of its Neovasc Reducer(TM) ("Reducer") device for the treatment of refractory/persistent angina pectoris, a common and disabling medical condition, and a major public health problem that affects millions of patients worldwide. The European Heart Journal is the official general cardiology journal of the European Society of Cardiology.
Refractory angina is a common and disabling clinical condition, and a major public health problem, which affects patients' quality of life, and has a significant impact upon health care resources. Persistent angina is common not only in patients who are not good candidates for revascularization, but also in patients following successful revascularization.
"Angina often persists following revascularization. The prevalence of this 'persistent' angina is as high as 25% after 1 year, and up to 45% after 3 years following revascularization," reported Dr. Maayan Konigstein, Department of Cardiology, Tel-Aviv Medical Center.
The coronary sinus Reducer is a novel technology designed to reduce disabling symptoms and improve quality of life of patients suffering from refractory angina. This clinical review serves to update the clinician as to current evidence and future perspectives of the optimal utilization of this innovative technology.
"At present, accumulating evidence supports the clinical benefit of the Reducer in significantly alleviating symptoms of angina in 70-80% of patients with obstructive Coronary Artery Disease who are not candidates for revascularization," commented Alexei Marko, CEO of Neovasc. "This type of dramatic results, along with a simple, safe and straightforward procedure, are underpinning Reducer's commercial success in Europe. With more than 500 cases performed to date, Reducer's impact in alleviating pain and improving quality of life continues to draw the attention of the medical community."
About the Neovasc Reducer(TM)
The Reducer is CE-marked in the European Union for the treatment of refractory angina, a painful and debilitating condition that occurs when the coronary arteries deliver an inadequate supply of blood to the heart muscle, despite treatment with standard revascularization or cardiac drug therapies. It affects millions of patients worldwide, who typically lead severely restricted lives as a result of their disabling symptoms, and its incidence is growing. The Reducer provides relief of angina symptoms by altering blood flow in the heart's circulatory system, thereby increasing the perfusion of oxygenated blood to ischemic areas of the heart muscle. Placement of the Reducer is performed using a minimally invasive transvenous procedure that is similar to implanting a coronary stent and is completed in approximately 20 minutes.
About Neovasc Inc.
Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products include the Neovasc Reducer(TM), for the treatment of refractory angina which is not currently available in the United States and has been available in Europe since 2015 and the Tiara(TM), for the transcatheter treatment of mitral valve disease, which is currently under investigation in the United States, Canada and Europe. The Company also sells a line of advanced biological tissue products that are used as key components in third-party medical products including transcatheter heart valves. For more information, visit: www.neovasc.com.
This news release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws regarding the Company's plans and expectations concerning its business, trends and other matters, including the Company's expectations relating to the number of patients that will not be candidates for conventional surgery, and the Company's commercial success in Europe. Words and phrases such as "growing", "begun", "continues" and "anticipated", and similar words or expressions, are intended to identify these forward-looking statements. Forward-looking statements are based on estimates and assumptions made by the Company in light of its experience and its perception of historical trends, current conditions and expected future developments, as well as other factors that the Company believes are appropriate in the circumstances. Many factors and assumptions could cause the Company's actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statements, including, without limitation, risks relating to the Company's litigation with CardiAQ, including the Company's ability to successfully appeal the validity of the awards as well as the ruling on inventorship, which create material uncertainty and which cast substantial doubt on the Company's ability to continue as a going concern; the substantial doubt about the Company's ability to continue as a going concern; risks relating to the Company's need for significant additional future capital and the Company's ability to raise additional funding; risks relating to claims by third parties alleging infringement of their intellectual property rights; the Company's ability to establish, maintain and defend intellectual property rights in its products; risks relating to results from clinical trials of the Company's products, which may be unfavorable or perceived as unfavorable; the Company's history of losses and significant accumulated deficit; risks associated with product liability claims, insurance and recalls; risks relating to competition in the medical device industry, including the risk that one or more competitors may develop more effective or more affordable products; risks relating to the Company's ability to achieve or maintain expected levels of market acceptance for its products, as well as the Company's ability to successfully build its in-house sales capabilities or secure third-party marketing or distribution partners; the Company's ability to convince public payors and hospitals to include the Company's products on their approved products lists; risks relating to new legislation, new regulatory requirements and the efforts of governmental and third party payors to contain or reduce the costs of healthcare; risks relating to increased regulation, enforcement and inspections of participants in the medical device industry, including frequent government investigations into marketing and other business practices; risks associated with the extensive regulation of the Company's products and trials by governmental authorities, as well as the cost and time delays associated therewith; risks associated with post-market regulation of the Company's products; health and safety risks associated with the Company's products and industry; risks associated with the Company's manufacturing operations, including the regulation of the Company's manufacturing processes by governmental authorities and the availability of two critical components of the Reducer; risk of animal disease associated with the use of the Company's products; risks relating to the manufacturing capacity of third-party manufacturers for the Company's products, including risks of supply interruptions impacting the Company's ability to manufacture its own products; risks relating to breaches of anti-bribery laws by the Company's employees or agents; risks associated with future changes in financial accounting standards and new accounting pronouncements; the Company's dependence upon key personnel to achieve its business objectives; the Company's ability to maintain strong relationships with physicians; risks relating to the sufficiency of the Company's management systems and resources in periods of significant growth; risks associated with consolidation in the health care industry, including the downward pressure on product pricing and the growing need to be selected by larger customers in order to make sales to their members or participants; the Company's ability to successfully identify and complete corporate transactions on favorable terms or achieve anticipated synergies relating to any acquisitions or alliances; anti-takeover provisions in the Company's constating documents which could discourage a third party from making a takeover bid beneficial to the Company's shareholders; risks relating to conflicts of interests among the Company's officers and directors as a result of their involvement with other issuers; and risks relating to the influence of significant shareholders of the Company over the Company's business operations and share price. These risk factors and others relating to the Company are discussed in greater detail in the "Risk Factors" section of the Company's Annual Information Form and in the Company's Management's Discussion and Analysis of Financial Condition and Results of Operations, each of which are included in the Company's Annual Report on Form 40-F (copies of which filings may be obtained at www.sedar.com or www.sec.gov). These factors should be considered carefully, and readers should not place undue reliance on the Company's forward-looking statements. The Company has no intention and undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
SOURCE Neovasc Inc.
View original content: http://www.newswire.ca/en/releases/archive/September2017/05/c4804.html
/CONTACT:
Investor Relations: Neovasc Inc., Chris Clark, 604 248-4138, cclark@neovasc.com
/Web site: www.neovasc.com
Copyright CNW Group 2017
(END) Dow Jones Newswires
September 05, 2017 07:00 ET (11:00 GMT)
Good morning guys, Hope everyone had a great weekend!
If there good quality, post them.
We understand the risk, I trust you.
To do right by investors!
Welcome buddy, now i know who you are.
Hope all is well!
New 52 week highs are a coming, Hoo Ha!
Thanks, I took a starter. Have a great weekend!
Thanks for the DD buddy!
Thanks!
VII 0.63 0.2199 +53.62 1,173,936 0.63 0.6301